

# HPTN 083-01 HPTN 083-01

Prevention for Teens



# HPTN 084-01

## Active Products

Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC



CAB

TDF/FTC

Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC




CAB

TDF/FTC

## Populations

About 50 adolescents assigned male at birth, including cisgender men who have sex with men, transgender women (TGW) and gender non-conforming people



About 50 cisgender adolescents assigned female at birth



## Locations

### United States:

Boston, MA; Chicago, IL; Memphis, TN



### Africa:

South Africa, Uganda, Zimbabwe



## Study Design

Single arm open label study evaluating the safety, tolerability and acceptability of CAB LA

Single arm open label study evaluating the safety, tolerability and acceptability of CAB LA

## Study Steps

### STEP 1

A daily oral pill for 5 weeks

CAB

### STEP 1

A daily oral pill for 5 weeks

CAB

### STEP 2

An injection every 8 weeks for 29 weeks



### STEP 2

An injection every 8 weeks for 29 weeks



### STEP 3

A daily oral pill for 48 weeks

TDF/FTC

### STEP 3

A daily oral pill for 48 weeks

TDF/FTC